Kollmar Otto, Junker Bastian, Rupertus Kathrin, Scheuer Claudia, Menger Michael D, Schilling Martin K
Department of General, Visceral, Vascular and Pediatric Surgery, University of Saarland, Homburg/Saar, Germany.
J Surg Res. 2008 Apr;145(2):295-302. doi: 10.1016/j.jss.2007.02.010. Epub 2007 Jun 11.
Previous studies have shown that liver resection enhances intrahepatic engraftment of CXCR-2-expressing colorectal cancer cells by the action of the CXC chemokine macrophage inflammatory protein (MIP)-2. Herein we studied how liver resection-associated MIP-2 affects extrahepatic tumor cell engraftment and whether MIP-2 also stimulates the growth of already established metastases.
Green fluorescent protein-transfected CT26.WT colorectal cancer cells were implanted into dorsal skinfold chambers of syngeneic BALB/c mice. Additionally, all animals underwent a 30% hepatectomy. To study MIP-2 in extrahepatic tumor cell engraftment, animals were treated with an anti-MIP-2 antibody, starting at the day of tumor cell implantation. To study MIP-2 in established metastases, anti-MIP-2 treatment was initiated at day 5 after tumor cell implantation. Hepatectomized animals without neutralization of MIP-2 served as controls. Tumor vascularization and growth as well as tumor cell migration, proliferation, apoptosis, and CXCR-2 expression were studied over 14 days using intravital fluorescence microscopy, histology, and immunohistochemistry.
Functional inhibition of MIP-2 significantly delayed extrahepatic tumor cell engraftment but not the growth of established metastases. The initial delay of engraftment was associated with a compensatory stimulation of vascularization and tumor cell migration when compared to controls (P < 0.05). Further, inhibition of tumor cell engraftment by initial anti-MIP-2 treatment was associated with a significant (P < 0.05) reduction of CXCR-2 expression and tumor cell apoptosis.
Our study indicates that MIP-2 is involved in extrahepatic engraftment of CT.26 colorectal cancer cells. The MIP-2/CXCR-2 signaling pathway may be a promising target for early antitumor therapy in patients undergoing liver resection.
先前的研究表明,肝切除通过CXC趋化因子巨噬细胞炎性蛋白(MIP)-2的作用增强了表达CXCR-2的结肠癌细胞在肝内的植入。在此,我们研究了肝切除相关的MIP-2如何影响肝外肿瘤细胞的植入,以及MIP-2是否也刺激已形成转移灶的生长。
将绿色荧光蛋白转染的CT26.WT结肠癌细胞植入同基因BALB/c小鼠的背部皮褶小室。此外,所有动物均接受30%肝切除术。为研究MIP-2在肝外肿瘤细胞植入中的作用,从肿瘤细胞植入当天开始,用抗MIP-2抗体对动物进行治疗。为研究MIP-2在已形成转移灶中的作用,在肿瘤细胞植入后第5天开始抗MIP-2治疗。未中和MIP-2的肝切除动物作为对照。使用活体荧光显微镜、组织学和免疫组织化学方法,在14天内研究肿瘤血管生成、生长以及肿瘤细胞迁移、增殖、凋亡和CXCR-2表达情况。
MIP-2的功能抑制显著延迟了肝外肿瘤细胞的植入,但不影响已形成转移灶的生长。与对照组相比,植入的初始延迟与血管生成和肿瘤细胞迁移的代偿性刺激有关(P<0.05)。此外,初始抗MIP-2治疗对肿瘤细胞植入的抑制与CXCR-2表达和肿瘤细胞凋亡的显著降低有关(P<0.05)。
我们的研究表明,MIP-2参与了CT26结肠癌细胞的肝外植入。MIP-2/CXCR-2信号通路可能是肝切除患者早期抗肿瘤治疗的一个有前景的靶点。